40
Participants
Start Date
February 23, 2016
Primary Completion Date
December 7, 2016
Study Completion Date
December 7, 2016
Riociguat (Adempas, BAY 63-2521)
0.5 mg, Oral (fasted conditions), 1 single dose
ATRIPLA
600 mg efavirenz, 200 mg emtricitabine, and 300 mg tenofovir disoproxil fumarate, i.e. 1 tablet, once daily
COMPLERA
200 mg emtricitabine, 25 mg rilpivirine, and 300 mg tenofovir disoproxil fumarate, i.e. 1 tablet, once daily
STRIBILD
150 mg elvitegravir, 150 mg cobicistat, 200 mg emtricitabine, and 300 mg tenofovir disoproxil fumarate, i.e. 1 tablet, once daily
TRIUMEQ
600 mg abacavir, 50 mg dolutegravir, and 300 mg lamivudine, i.e. 1 tablet, once daily
Antiretroviral protease inhibitor
Any approved antiretroviral protease inhibitor such as atazanavir, darunavir, indinavir, ritonavir, and saquinavir ; consistent with the most recent prescribing information documents
Orlando
Boston
Lead Sponsor
Bayer
INDUSTRY